Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

2014 ASCO Annual Meeting

30 May - 3 Jun 2014

McCormick Place, Chicago, United States of America

Pooled analysis of two phase III trials shows eribulin improves survival in advanced breast cancer

Pooled analysis of two phase III trials shows eribulin improves survival in advanced breast cancer

ASCO 2014: PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma

ASCO 2014: PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma

ASCO 2014: Adjuvant ipilimumab improves recurrence-free survival in high-risk melanoma

ASCO 2014: Adjuvant ipilimumab improves recurrence-free survival in high-risk melanoma

ASCO 2014: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

ASCO 2014: HPV-targeted adoptive T cell therapy may provide a new strategy for advanced cervical cancer

ASCO 2014: Ipilimumab with nivolumab achieves long-term survival in advanced melanoma

ASCO 2014: Ipilimumab with nivolumab achieves long-term survival in advanced melanoma

ASCO 2014: Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer

ASCO 2014: Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in...

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

ASCO 2014: Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone...

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

ASCO 2014: First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in...

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer

ASCO 2014: Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast...

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced differentiated thyroid cancer

ASCO 2014: Lenvatinib yields high response rates and delays progression for radioiodine-resistant, advanced...

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer

ASCO 2014: New combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent...

ASCO 2014: Discontinuing statins near the end of life is safe, improves patient quality of life

ASCO 2014: Discontinuing statins near the end of life is safe, improves patient quality of life

ASCO 2014: Early, phone-based, palliative care support improves caregiver quality of life

ASCO 2014: Early, phone-based, palliative care support improves caregiver quality of life

ASCO 2014: Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

ASCO 2014: Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and bone metastases, compared to the standard monthly treatment

ASCO 2014: Less frequent zoledronic acid is safe, and has comparable efficacy for women with breast cancer and...

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone receptor-negative breast cancer

ASCO 2014: LHRH analogue goserelin helps preserve fertility among women undergoing chemotherapy for hormone...

Guideline update recommends tamoxifen for up to 10 years for women with non-metastatic hormone receptor positive breast cancer

Guideline update recommends tamoxifen for up to 10 years for women with non-metastatic hormone receptor positive...

New afatinib data suggests hope for non-small-cell lung adenocarcinoma patients with EGFR mutations

New afatinib data suggests hope for non-small-cell lung adenocarcinoma patients with EGFR mutations

PV-10 data for break through therapy designation application highlighted by ASCO

PV-10 data for break through therapy designation application highlighted by ASCO

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing

Delaying androgen deprivation therapy may be safe for men with prostate cancer relapse detected by PSA testing

PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis

PLX3397 may provide a new treatment option for patients with recurrent pigmented villonodular synovitis

Study projects nationwide LDCT screening will identify more – and earlier-stage – lung cancers, but comes with substantial medicare costs

Study projects nationwide LDCT screening will identify more – and earlier-stage – lung cancers, but comes with...

Obesity substantially increases breast cancer mortality only in women with pre-menopausal ER disease

Obesity substantially increases breast cancer mortality only in women with pre-menopausal ER disease

More from ecancer